End Stage Cancer — An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients
Citation(s)
Tang ST, Liu TW, Lai MS, Liu LN, Chen CH Concordance of preferences for end-of-life care between terminally ill cancer patients and their family caregivers in Taiwan. J Pain Symptom Manage. 2005 Dec;30(6):510-8.
Tang ST, Liu TW, Lai MS, McCorkle R Discrepancy in the preferences of place of death between terminally ill cancer patients and their primary family caregivers in Taiwan. Soc Sci Med. 2005 Oct;61(7):1560-6. Epub 2005 Apr 7.
Tang ST, Liu TW, Tsai CM, Wang CH, Chang GC, Liu LN Patient awareness of prognosis, patient-family caregiver congruence on the preferred place of death, and caregiving burden of families contribute to the quality of life for terminally ill cancer patients in Taiwan. Psychooncology. 2008 Dec;17(12):1202-9. doi: 10.1002/pon.1343.
Tang ST, Wu SC, Hung YN, Chen JS, Huang EW, Liu TW Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol. 2009 Sep 20;27(27):4613-8. doi: 10.1200/JCO.2008.20.5096. Epub 2009 Aug 24.
Tang ST, Wu SC, Hung YN, Huang EW, Chen JS, Liu TW Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000-2006. Ann Oncol. 2009 Feb;20(2):343-8. doi: 10.1093/annonc/mdn602. Epub 2008 Sep 2.
An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
